Permitting pharmacists to dispense the drug Ivermectin by means of a standing order and establishing a commission to study the use of Ivermectin to treat Covid-19.
Impact
If enacted, HB1022 will significantly amend existing state law regarding pharmacy practices by providing pharmacists with a new delegated authority to dispense Ivermectin without a prior prescription. This could accelerate Ivermectin availability, aligning with public health responses to Covid-19. However, this authority is set to be temporary, with sunset provisions aiming to review its necessity by July 1, 2024. The accompanying commission will play a critical role in assessing the drug's effectiveness and determining whether to make the dispensing authority permanent.
Summary
House Bill 1022 permits pharmacists in New Hampshire to dispense the drug Ivermectin based on a standing order from licensed physicians or advanced practice registered nurses. This legislation aims to enable easier access to Ivermectin, especially for potential treatments related to Covid-19. Additionally, the bill establishes a commission tasked with studying the efficacy and implications of Ivermectin usage for Covid-19 treatment, suggesting that a rigorous analysis of national data and existing studies is integral to the bill's implementation.
Sentiment
The sentiment surrounding the bill appears mixed, with supporters advocating for greater access to Ivermectin as a potential treatment for patients, while critics express concerns about hastily permitting a drug that may lack proven benefits against Covid-19. The legislative discourse highlighted debates on public health prioritization against the risk of promoting an unverified treatment, suggesting a polarized perspective on the bill's necessity and implications for health safety.
Contention
Notable points of contention during discussions included whether Ivermectin should be widely promoted for Covid-19 treatment, especially considering that recipients must acknowledge the lack of proven benefits attached to its usage. Furthermore, the establishment of a state commission raises questions about accountability and oversight in the ongoing study of Ivermectin's effects and whether the standing order mechanism effectively addresses potential misuse or over-prescription by pharmacists.